AURKB and Miyoshi myopathy: Recently, Bonnet and coauthors provided evidences on the possibility to utilize barasertib, an Aurora B kinase inhibitor, as a new therapeutic strategy in both wild-type BRAF and vemurafenib-resistant BRAFV600E melanoma, stressing the idea that Aurora B kinase is a potential target in the therapy of MM [18].